David A. Siegel Janux Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$35.12 - $64.78 $2.24 Million - $4.13 Million
-63,700 Reduced 76.75%
19,300 $808,000
Q1 2024

May 15, 2024
BUY
$7.93 - $49.75 $471,042 - $2.96 Million
59,400 Added 251.69%
83,000 $3.12 Million
Q4 2023

Feb 14, 2024
BUY
$5.85 - $11.7 $138,060 - $276,120
23,600 New
23,600 $253,000

Others Institutions Holding JANX

# of Institutions
166
Shares Held
37.6M
Call Options Held
85.3K
Put Options Held
654K
View Full List

About Janux Therapeutics, Inc.

JANX Quotes by TradingView
  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email